DILANTIN-125

Asset

Stage
Approved
Modality
Not known
Target
Not known
1
Indication
46
Trials
1
Developer

Approved by the FDA on Jan 6, 1953 (NDA008762). FDA

Indications

1
  • No named disease

    Approved, FDA, Jan 6, 1953

In the full profile

  • Target and mechanism1
  • Owner and partners1
  • Trials46
  • Evidence for its targets1
  • Competitors1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets